710GO FOR GENERAL OBESITY

710GO, our lead asset, is an oral dual MC3R/MC4R agonist entering Phase 1 study as a next generation treatment for general obesity.

A man and woman embrace and smile outdoors, surrounded by other people in a park setting.

In compelling non-human primate studies, 710GO has shown weight loss comparable to GLP-1 agonists with a healthier, more durable product profile

Kalohexis addresses shortcomings in the standard-of-care in a market with massive unmet need

Obese Adults in
the US
Annual medical
expenditures
of US Healthcare
Spending

710GO is designed to activate the melanocortin system to change the metabolic set point, “resetting the thermostat” that regulates appetite and energy expenditure to induce durable weight loss. Through dual MC3R/MC4R activation, rather than simply suppressing appetite, 710GO drives healthier weight loss that preserves lean muscle mass and avoids the common side effects and limitations of standard of care GLP-1 agonists, including poor tolerability and weight rebound following discontinuation. 710GO can be used as a monotherapy and also enhances weight loss when added to standard-of-care anti-obesity weight loss regimens.

710GO represents a pivotal shift in weight loss treatment

1

Effective Weight Loss

Achieved 11.7% weight loss in 13 weeks in primate models of diet-induced obesity, on par with GLP-1s.

2

Minimal Weight Regain

Unlike GLP-1s, 710GO shows minimal rebound weight gain after treatment discontinuation in animal studies.

3

Superior Safety Profile

A cardiac-safe molecule with exceptionally clean safety signals, addressing patient tolerability concerns.

4

Optimized Combinations

Combines with semaglutide for enhanced results and reduced GLP-1 doses.

5

Accessible

With an oral-dosage format, weight loss treatments are more accessible, tolerable, and affordable.